Join
Live feed
·
PRReleasevia Quantisnow
Biofrontera Inc. logo

Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma

ByQuantisnow·Wall Street's wire, on your screen.
BFRI· Biofrontera Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BFRI (Biofrontera Inc.) and more on Quantisnow.